…
DIAGNOS Inc. provides software-based services for healthcare sector in Canada, the United States, Mexico, Chile, and internationally. It offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy, as well as allows eye care specialist to visualize normal retinal landmarks and pathological changes. The company also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Publicly available information on Diagnos Inc (ADK.V) is limited, which constrains definitive description of its operations. Disclosures indicate the company is an early-stage diagnostics developer and long-term growth drivers could include regulatory approvals, product validation and commercialization partnerships. Investors may find exposure to potential upside if the company successfully brings technology to market.
Material risks include an early-stage profile with limited operating history or revenue, dependence on regulatory and commercial execution, ongoing financing and dilution risk, and low trading liquidity.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Income before tax | -4.29M | -3.12M | -2.48M | -2.61M | -2.05M |
| Net income | -4.29M | -3.12M | -2.48M | -2.61M | -2.05M |
| Selling general administrative | 2.88M | 1.77M | 1.93M | 2.24M | 1.94M |
| Gross profit | -0.94M | -0.84M | -0.31M | -0.42M | -0.35M |
| Reconciled depreciation | 0.13M | 0.12M | 0.10M | 0.11M | 0.09M |
| Ebit | - | -2.60M | - | -2.55M | -2.04M |
| Ebitda | - | -2.48M | -2.10M | -2.45M | -1.93M |
| Depreciation and amortization | - | 0.12M | - | 0.10M | 0.11M |
| Operating income | -3.81M | -2.60M | -2.22M | -2.55M | -2.02M |
| Other operating expenses | - | 2.77M | - | 3.10M | 2.55M |
| Interest expense | 0.59M | 0.55M | 0.28M | 0.05M | 0.03M |
| Tax provision | - | - | 0.00M | 0.00M | 0.00M |
| Interest income | 0.05M | 0.01M | 0.01M | 0.01M | 0.02M |
| Net interest income | -0.54M | -0.54M | -0.27M | -0.05M | -0.03M |
| Income tax expense | - | 0.00M | - | 0.15M | 0.30M |
| Total revenue | 0.10M | 0.17M | 0.49M | 0.44M | 0.27M |
| Total operating expenses | 3.91M | 1.76M | 2.71M | 2.24M | 1.94M |
| Cost of revenue | 1.05M | 1.01M | 0.79M | 0.86M | 0.61M |
| Total other income expense net | 0.07M | -0.52M | 0.01M | 0.10M | 0.26M |
| Net income from continuing ops | -4.29M | -3.12M | -2.48M | -2.61M | -2.05M |
| Net income applicable to common shares | - | - | - | -2.61M | -2.05M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 3.64M | 0.66M | 0.82M | 1.54M | 1.95M |
| Other current assets | - | 0.02M | 0.02M | 0.02M | 0.03M |
| Total liab | 3.40M | 3.72M | 2.77M | 1.66M | 0.82M |
| Total stockholder equity | 0.23M | -3.05M | -1.95M | -0.11M | 1.13M |
| Other current liab | - | 0.19M | 0.01M | 0.01M | 0.00M |
| Common stock | - | 37.70M | 35.91M | 35.68M | 34.76M |
| Capital stock | 44.96M | 37.70M | 35.91M | 35.68M | 34.76M |
| Retained earnings | -54.93M | -50.65M | -47.53M | -44.99M | -42.38M |
| Other assets | - | - | - | - | 0.03M |
| Cash | 0.09M | 0.22M | 0.30M | 0.42M | 0.36M |
| Total current liabilities | 3.12M | 1.62M | 0.72M | 0.66M | 0.55M |
| Current deferred revenue | - | 0.01M | - | - | - |
| Net debt | 2.80M | 2.97M | 1.77M | 0.54M | - |
| Short term debt | - | 1.09M | - | - | - |
| Short long term debt | 2.69M | 0.98M | 0.17M | 0.12M | 0.12M |
| Short long term debt total | - | 3.19M | - | - | - |
| Other stockholder equity | - | - | 9.66M | 9.20M | 8.76M |
| Property plant equipment | - | - | 0.25M | 0.25M | 0.33M |
| Total current assets | 3.47M | 0.41M | 0.57M | 1.29M | 1.59M |
| Long term investments | - | - | - | 0.00M | 0.03M |
| Net tangible assets | - | - | - | -0.11M | 1.13M |
| Short term investments | 3.15M | - | 0.00M | 0.50M | 1.00M |
| Net receivables | 0.01M | 0.17M | 0.24M | 0.33M | 0.18M |
| Long term debt | 0.20M | 1.95M | 1.90M | 0.83M | 0.04M |
| Accounts payable | 0.17M | 0.33M | 0.29M | 0.28M | 0.19M |
| Accumulated other comprehensive income | - | 9.89M | - | - | - |
| Non current assets total | 0.17M | 0.26M | 0.25M | 0.25M | 0.36M |
| Capital lease obligations | 0.18M | 0.26M | 0.24M | 0.23M | 0.31M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Investments | -3.10M | -0.01M | 0.50M | 0.53M | 0.30M |
| Change to liabilities | - | - | -0.00M | 0.12M | 0.07M |
| Total cashflows from investing activities | - | - | 0.47M | 0.50M | 0.26M |
| Net borrowings | -0.38M | - | 1.40M | 0.89M | -0.21M |
| Total cash from financing activities | 6.62M | 2.35M | 1.28M | 1.60M | 0.88M |
| Change to operating activities | - | - | 0.01M | 0.00M | 0.10M |
| Net income | -4.29M | -3.12M | -2.48M | -2.61M | -2.05M |
| Change in cash | -0.13M | -0.08M | -0.12M | 0.06M | -0.21M |
| Begin period cash flow | 0.22M | 0.30M | 0.42M | 0.36M | 0.57M |
| End period cash flow | 0.09M | 0.22M | 0.30M | 0.42M | 0.36M |
| Total cash from operating activities | -3.64M | -2.41M | -1.88M | -2.04M | -1.36M |
| Issuance of capital stock | 7.28M | 1.64M | 0.45M | 0.72M | 1.11M |
| Depreciation | 0.13M | 0.12M | 0.10M | 0.11M | 0.09M |
| Other cashflows from investing activities | - | - | -0.00M | 0.00M | 0.01M |
| Dividends paid | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to inventory | - | - | - | 0.00M | -0.12M |
| Change to account receivables | -0.00M | 0.10M | 0.08M | -0.14M | 0.14M |
| Other cashflows from financing activities | - | -0.01M | -0.12M | 0.98M | 0.02M |
| Change to netincome | - | - | 0.39M | 0.48M | 0.30M |
| Capital expenditures | 0.01M | 0.01M | 0.02M | 0.03M | 0.04M |
| Change in working capital | -0.24M | 0.15M | 0.09M | -0.01M | 0.31M |
| Stock based compensation | 0.29M | 0.18M | 0.17M | 0.17M | 0.43M |
| Other non cash items | 0.29M | 0.52M | 0.12M | 0.03M | 0.03M |
| Free cash flow | -3.65M | -2.42M | -1.91M | -2.07M | -1.40M |
Sector: Healthcare Industry: Health Information Services
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ADK Diagnos Inc |
0.03 7.04% |
0.38 | - | 10.00 | 411.24 | 18.74 | 389.06 | -6.16 |
| NURS Hydreight Technologies Inc |
-0.04 1.42% |
2.77 | 406.00 | 25.91 | 7.85 | 20.38 | 7.45 | 109.02 |
| NXG NexgenRX Inc. |
-0.04 6.06% |
0.62 | 39.00 | 32.68 | 1.55 | 4.64 | 1.39 | 7.84 |
| PTEC Principal Technologies Inc |
- -% |
0.32 | - | - | 62.75 | 355.42 | 72.08 | -0.81 |
| CHS Comprehensive Healthcare Systems Inc |
-0.01 1.52% |
0.33 | - | - | 4.44 | 13.23 | 3.83 | 26.88 |
DIAGNOS Inc. provides software-based services for healthcare sector in Canada, the United States, Mexico, Chile, and internationally. It offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy, as well as allows eye care specialist to visualize normal retinal landmarks and pathological changes. The company also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Andre Larente | CEO, Pres & Exec. Director | NA |
| Mr. Marc-André Massue | VP of Fin., CFO & Sec. | NA |
| Mr. Guillermo Moreno Robles | VP of Sales | NA |
| Mr. Martin Beland | Director of Marketing | NA |
| Mr. Andre Larente | CEO, President & Executive Chairman | NA |
| Mr. Marc-André Massue | VP of Finance, CFO & Secretary | NA |
| Mr. Yves-Stéphane Couture | Chief Operating Officer | NA |
| Mr. Marc-André Massue CA, CPA | VP of Finance, CFO & Secretary | NA |
| Mr. Andre Larente | CEO, President & Executive Director | NA |
| Dr. Ismail Ben Ayed | Chief Artificial Intelligence Scientist | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.